Why Is Physical Therapy Important for CIDP Recovery?
At a Glance
Physical therapy is important in CIDP recovery because IVIG can control the immune attack without fully restoring muscle strength, balance, endurance, or mobility. An individualized rehabilitation plan helps rebuild function, manage fatigue, reduce fall risk, and support independence.
In this answer
3 sections
A common misconception about recovering from Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is that medications alone will restore full function. If you are receiving intravenous immunoglobulin (IVIG), it is easy to wonder why physical therapy is necessary when the medication is already working. The answer lies in the division of labor in your care: immunotherapies control the immune activity, while physical therapy helps you maximize the function and independence of your healing nerves and muscles.
While IVIG suppresses the immune-mediated nerve injury and reduces the risk of relapses [1][2], it does not automatically restore muscle strength or retrain your body’s balance systems. Residual symptoms are extremely common, and rehabilitation is an important complement to your medical care to address these functional consequences [1][3].
Disease Control vs. Functional Recovery
Immunotherapies like IVIG are highly effective at halting the active immune attack on your peripheral nerves. They give the nerves a chance to heal, which can improve your baseline strength and disability levels [2][4]. However, even when treatment successfully controls the disease, significant sensory and motor deficits often remain [5].
During the active phase of CIDP, muscles can atrophy (shrink and weaken) due to disuse and poor nerve signaling. IVIG cannot rebuild this muscle mass on its own. Rebuilding strength and endurance requires an individualized physical rehabilitation plan.
How Physical Therapy Helps You Recover
Physical therapy targets the physical impairments left behind by the disease. A specialized physical therapist will first assess your strength, sensation, walking ability, and fall risk, and then design a customized program focusing on:
- Rebuilding Muscle Strength: CIDP frequently causes symmetric proximal and distal muscle weakness (weakness in muscles close to your core like your thighs and shoulders, as well as those further away like your hands and feet) [6]. Specialized resistance training can help strengthen these muscles safely. One small, 12-week study found that tailored resistance exercise improved tested muscle strength by roughly 14% in a group of patients with CIDP, showing that guided exercise can be beneficial [7].
- Improving Aerobic Capacity: Physical deconditioning happens quickly when movement is limited. Supervised aerobic exercise has been shown to improve cardiovascular fitness (measured as maximal oxygen consumption) in small groups of CIDP patients [7].
- Managing Fatigue: Severe fatigue is incredibly common in CIDP and can persist even after apparent neurological recovery [8][9]. However, ongoing fatigue should also be evaluated for other causes like poor sleep, medications, or ongoing disease activity. A physical therapist can help you build endurance safely while teaching you pacing and energy management techniques. (You may also be referred to an occupational therapist to help with energy conservation strategies for daily tasks.)
- Restoring Balance and Mobility: CIDP often causes large-fiber sensory impairment (loss of the ability to feel touch, vibration, and joint position) and sensory ataxia (a lack of muscle coordination and balance because your brain cannot easily sense where your limbs are) [10]. Physical therapy focuses heavily on sensory compensation strategies, safe walking (gait) training, and reducing your risk of falls [6]. They may also recommend orthoses (braces) or assistive devices like a cane or walker to keep you safe.
Maintaining Your Gains and Exercising Safely
The benefits of physical therapy require ongoing, sustainable maintenance. Research from small exercise studies suggests that when patients stop exercising completely, their strength and aerobic gains can decline back toward baseline over time [11].
Because CIDP can have a variable course [12], your routine must be individualized. Your physical therapist and neurologist will use objective measurements—like grip dynamometry (a device used to measure hand grip strength) and walking velocity (how fast you can walk safely)—to track your progress and adjust your routine [13][14].
Safety Warning: You should not start or intensify an exercise routine without an individualized assessment. Nerve-related weakness does not respond exactly like ordinary muscle fatigue, and overexertion can increase your fall risk. If you experience new, sustained weakness, repeated falls, loss of previously regained function, or fatigue that persists into the next day, do not assume it is just “exercise fatigue.” Contact your neurologist, as these could be signs of a CIDP relapse or a need to adjust your immunotherapy dose [15][16].
Think of physical therapy as an active, customized treatment for your functional mobility. While your medications handle the immune system, your care team works together to help you safely live as actively and independently as possible.
Common questions in this guide
Why do I need physical therapy if IVIG is helping my CIDP?
What does physical therapy for CIDP usually include?
Can exercise cause a CIDP relapse or make my symptoms worse?
How can physical therapy help with CIDP fatigue and balance problems?
How will my care team know whether CIDP rehabilitation is working?
When should I contact my neurologist during CIDP recovery?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.What specific objective tests (like grip dynamometry or walking speed) will we use to track my physical progress between IVIG infusions?
- 2.Can you refer me to a physical therapist who has experience with demyelinating neuropathies or neuromuscular diseases?
- 3.What intensity and amount of activity are safe for me right now?
- 4.Should I be using a cane, walker, brace, or making home safety changes?
- 5.Who should I contact if my symptoms worsen between infusions or if I experience repeated falls?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (16)
- 1
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force-Second revision.
Van den Bergh PYK, van Doorn PA, Hadden RDM, et al.
European journal of neurology 2021; (28(11)):3556-3583 doi:10.1111/ene.14959.
PMID: 34327760 - 2
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.
Merkies ISJ, van Schaik IN, Léger JM, et al.
Journal of the peripheral nervous system : JPNS 2019; (24(1)):48-55 doi:10.1111/jns.12302.
PMID: 30672091 - 3
Clinical outcome of CIDP one year after start of treatment: a prospective cohort study.
Bus SRM, Broers MC, Lucke IM, et al.
Journal of neurology 2022; (269(2)):945-955 doi:10.1007/s00415-021-10677-5.
PMID: 34173873 - 4
Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K, van Doorn PA, Bengrine T, et al.
European journal of neurology 2021; (28(5)):1677-1683 doi:10.1111/ene.14742.
PMID: 33460483 - 5
Intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): mechanisms of action and clinical and genetic considerations.
Dalakas MC, Latov N, Kuitwaard K
Expert review of neurotherapeutics 2022; (22(11-12)):953-962 doi:10.1080/14737175.2022.2169134.
PMID: 36645654 - 6
[Typical CIDP: Update of the Pathogenesis, Diagnosis, and Treatment].
Kuwabara S
Brain and nerve = Shinkei kenkyu no shinpo 2024; (76(5)):515-519 doi:10.11477/mf.1416202637.
PMID: 38741490 - 7
Resistance training and aerobic training improve muscle strength and aerobic capacity in chronic inflammatory demyelinating polyneuropathy.
Markvardsen LH, Overgaard K, Heje K, et al.
Muscle & nerve 2018; (57(1)):70-76 doi:10.1002/mus.25652.
PMID: 28345260 - 8
Fatigue, Pain, Anxiety and Depression in Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Merkies IS, Kieseier BC
European neurology 2016; (75(3-4)):199-206 doi:10.1159/000445347.
PMID: 27077919 - 9
Non-sensorimotor symptoms in chronic inflammatory demyelinating polyneuropathy.
Klostermann F, Steiner OL
Journal of neurology 2026; (273(3)).
PMID: 41774214 - 10
History, Diagnosis, and Management of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
Dyck PJB, Tracy JA
Mayo Clinic proceedings 2018; (93(6)):777-793 doi:10.1016/j.mayocp.2018.03.026.
PMID: 29866282 - 11
Muscle Strength and Aerobic Capacity in Patients with CIDP One Year after Participation in an Exercise Trial.
Markvardsen LK, Carstens AR, Knak KL, et al.
Journal of neuromuscular diseases 2019; (6(1)):93-97 doi:10.3233/JND-180344.
PMID: 30507584 - 12
[Treatment Options for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP): With a Focus on Immunoglobulin Treatment].
Koga M, Iijima M, Fukushima T, Kaida K
Brain and nerve = Shinkei kenkyu no shinpo 2021; (73(11)):1275-1284 doi:10.11477/mf.1416201930.
PMID: 34759066 - 13
Measuring disease activity and clinical response during maintenance therapy in CIDP: from ICE trial outcome measures to future clinical biomarkers.
Katzberg HD, Latov N, Walker FO
Neurodegenerative disease management 2017; (7(2)):147-156 doi:10.2217/nmt-2016-0058.
PMID: 28112008 - 14
Evaluating Grasp Function in Patients With Chronic Inflammatory Demyelinating Polyneuropathy Using Dynamometers: A Comprehensive Review.
Tsoumanis P, Chatzoglou T, Smyris TI, et al.
Journal of clinical medicine research 2025; (17(3)):136-144 doi:10.14740/jocmr6179.
PMID: 40115839 - 15
Neuraxial Anesthesia and Lower Extremity Peripheral Nerve Blocks for Ankle Surgery in a Patient With Chronic Inflammatory Demyelinating Polyneuropathy: A Case Report.
Wells AV, Akerman M, Weinberg RY
A&A practice 2020; (14(2)):51-53 doi:10.1213/XAA.0000000000001140.
PMID: 31789825 - 16
Maintenance Intravenous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: 18-Month Post-marketing Surveillance in 103 Patients.
Kuwabara S, Oh A, Arakawa M, et al.
Internal medicine (Tokyo, Japan) 2025; (64(4)):535-541 doi:10.2169/internalmedicine.3661-24.
PMID: 39019607
This page explains how physical therapy may complement IVIG in CIDP for informational purposes only and does not constitute medical advice. Ask your neurologist and physical therapist to tailor exercise and safety recommendations to you.
Get notified when new evidence is published on Chronic inflammatory demyelinating polyneuropathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.